课题基金 / 基金详情

Defining New Human Immunodeficiency and Immunodysregulation Disorders

Defining New Human Immunodeficiency and Immunodysregulation Disorders
定义新的人类免疫缺陷和免疫失调疾病
批准号:
7964691
负责人:
Helen Su
金额:
$77.09万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Helen Su的其他基金

相似基金

相关文献

中文摘要
翻译
除了缺乏已知诊断的免疫缺陷和免疫失调疾病的独特患者外,我们的患者还包括自身免疫性淋巴细胞增生性综合征(ALPS)或caspase-8缺乏症(CEDS)、常见变异性免疫缺陷综合征(CVID)、x连锁淋巴细胞增生性综合征(XLP)和Evans综合征的患者。2009年,我们利用功能筛查和基因测序排除已知疾病,评估了过去一年中103例新患者及其亲属,累计评估了350例。大约有20种正在使用生化分析、基因表达微阵列、流式细胞分析、体外功能测试和其他技术进行深入研究。这些实验为以前与疾病无关的新候选基因的测序提供了线索。此外,我们开始使用比较基因组杂交(CGH)阵列和其他基因组技术,以公正的方式确定新的免疫疾病的遗传原因。
英文摘要
Besides unique patients with immunodeficiency and immunodysregulation disorders lacking known diagnoses, our intake includes patients with variants of autoimmune lymphoproliferative syndrome (ALPS) or caspase-8-deficiency state (CEDS), common variable immunodeficiency (CVID), X-linked lymphoproliferative syndrome (XLP), and Evans syndrome. In 2009, we evaluated 103 new patients and their relatives over the past year, for 350 cumulatively, using functional screening and gene sequencing to exclude known disease. About 20 are being intensively studied using biochemical analyses, gene expression microarrays, flow cytometric analyses, in vitro functional tests, and other technologies. These experiments have provided leads for sequencing of new candidate genes not previously associated with disease. Additionally, we started using comparative genomic hybridization (CGH) arrays and other genomic technologies to determine genetic causes of new immunological diseases in an unbiased manner. Our most important advance in 2009 was the discovery that autosomal recessive loss-of-function mutations in the dedicator of cytokinesis 8 (DOCK8) gene cause a new form of combined immunodeficiency. Patients have recurrent upper and lower respiratory tract infections, severe and persistent viral infections of the skin (caused by herpes simplex virus, molluscum contagiosum, and human papillomavirus), severe food and other allergies associated with anaphylaxis, and cancers. Their peripheral blood contains low numbers of and poorly functioning lymphocytes, including the CD8 T cells that are important in fighting viral infections, as well as high levels of immunoglobulin E and eosinophils that contribute to allergy. Our discovery of this new disease and its genetic cause now facilitates the diagnosis and further study of affected patients. Moreover, since little is known about DOCK8, studying how it normally works to regulate immune cells in preventing infections, allergies, and cancers, may help us better understand why patients in the general population suffer similar problems. In 2009, we also contributed to two other advances focused on X-linked lymphoproliferative disease (XLP). In this disease, boys die from infection with Epstein-Barr virus (EBV), unless they receive a bone marrow transplant to replace their defective lymphocytes. EBV is a common virus that causes no symptoms or a self-limited infectious mononucleosis in healthy people. Patients with XLP can also develop lymphoproliferative disease, including lymphomas, but why this happens was not clear. Our work established that this occurs because the product of the gene that is mutated in most forms of XLP, SH2D1A (SAP), normally functions not only in activating lymphocytes but also in linking this signal to the signal for lymphocyte death. Because this signal is missing in most XLP patients, patients abnormally accumulate lymphocytes, which can predispose them to developing cancers. Finally, we also helped establish the utility of a rapid flow cytometry-based way to diagnose a form of XLP due to BIRC4 (XIAP) mutations. Because XLP mimics other diseases and requires curative bone marrow transplantation, this work will improve patient diagnosis and care.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Host factors contributing to susceptibility to COVID-19 disease
Molecular Mechanisms of Familial Hemophagocytic Lymphohistiocytosis
Defining New Human Immunodeficiency and Immunodysregulation Disorders
Defining New Human Immunodeficiency and Immunodysregulation Disorders
海外基金